JAK Inhibitors in 2026: Powerful, Effective — and Used More Carefully

JAK inhibitors revolutionised rheumatoid arthritis in the late 2010s. The 2022 ORAL Surveillance trial then forced a major rethink on cardiovascular and malignancy risk, particularly in older smokers. In 2026, rheumatology uses JAKs as effectively as ever — but with much sharper patient selection.

What ORAL Surveillance changed

• Tofacitinib showed higher rates of MACE and malignancy versus TNF inhibitors in RA patients ≥ 50 with at least one cardiovascular risk factor.
• Regulators now mandate TNF inhibitor failure before JAK use in higher-risk groups in many jurisdictions.
• Class effect — the cautions extend to other JAK inhibitors with similar pharmacology.

Where JAK inhibitors still shine

• Younger patients (< 50) without cardiovascular or malignancy risk factors — excellent benefit-risk profile.
• Oral convenience over injectable biologics — significant adherence advantage for some patients.
• Beyond RA — atopic dermatitis, psoriatic arthritis, ulcerative colitis, alopecia areata.

How rheumatologists are choosing now

• Cardiovascular risk assessment before starting JAK in any patient ≥ 50 — smoking, hypertension, diabetes, dyslipidaemia.
• Cancer screening up to date — colonoscopy, mammography, skin checks per age guidelines.
• Shingles vaccination ideally before starting — JAKs increase herpes zoster risk; recombinant zoster vaccine reduces it.

What this means for patients and practising clinicians

JAK inhibitors aren't out of favour — they're being used more carefully. If you're on one, the right conversation with your rheumatologist in 2026 covers cardiovascular risk control, cancer screening, and zoster vaccination — not stopping the drug.

*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*